8-K - Drugs Made In America Acquisition Corp. (0002028614) (Filer)
Published . Updated .
Filed: 2026-10-21 AccNo: 0001213900-26-111421 Size: 304 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Directly affected
- DMAA Drugs Made In America Acquisition
Named in this report.
- DMAAR Drugs Made In America Acquisition Corp
SEC 8-K filing -> direct issuer disclosure -> DMAAR
Indirectly affected
- SPY SPDR S&P 500
The broad U.S. stock market
- TLT iShares 20+ Year Treasury Bond
Long-term U.S. government bonds
- QQQ Invesco QQQ
Large technology stocks
- GLD SPDR Gold Shares
Gold can move with the broad market
Price reaction, T-5 to T+3
Filed: 2026-10-21 AccNo: 0001213900-26-111421 Size: 304 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Who gains and who loses around Drugs Made In America Acquisition (DMAAR)
Companies carried with this story
- DMAAR Drugs Made In America Acquisition
Drugs Made In America Acquisition (DMAAR) is linked, with no stored direction, high confidence in the 21 Oct 2026 story “8-K - Drugs Made In America Acquisition Corp. (0002028614) (Filer).” Reason on file: SEC 8-K filing -> direct issuer disclosure -> DMAAR
Drugs Made In America Acquisition (DMAAR)
The 21 Oct 2026 story “8-K - Drugs Made In America Acquisition Corp. (0002028614) (Filer)” names Drugs Made In America Acquisition (DMAAR) because of this story.
The link for Drugs Made In America Acquisition (DMAAR) is this: SEC 8-K filing -> direct issuer disclosure -> DMAAR
Dates in the story, and the Drugs Made In America Acquisition (DMAAR) price range
DMAAR traded between 0.12 and 0.12 across 1 sessions. The latest close on file is 0.12.
A simple score for Drugs Made In America Acquisition (DMAAR)
14 out of 100
“8-K - Drugs Made In America Acquisition Corp. (0002028614) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.